{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T11:04:12Z","timestamp":1771067052610,"version":"3.50.1"},"reference-count":80,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1053\/j.seminhematol.2013.11.001","type":"journal-article","created":{"date-parts":[[2013,11,14]],"date-time":"2013-11-14T10:18:23Z","timestamp":1384424303000},"page":"25-34","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["The Changing Landscape of Peripheral T-Cell Lymphoma in the Era of Novel Therapies"],"prefix":"10.1053","volume":"51","author":[{"given":"Lionel","family":"Karlin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bertrand","family":"Coiffier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2013.11.001_bib1","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib2","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","article-title":"Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001","volume":"107","author":"Morton","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib3","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1365-2141.2005.05478.x","article-title":"The International Prognostic Index determines the outcome of patients with nodal mature T-cell lymphomas","volume":"129","author":"Sonnen","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib4","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1182\/blood-2010-09-310342","article-title":"Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project","volume":"117","author":"Weisenburger","year":"2011","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib5","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.beha.2013.04.005","article-title":"Treatment strategies for peripheral T-cell lymphomas","volume":"26","author":"Foss","year":"2013","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib6","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/cncr.20999","article-title":"Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience","volume":"103","author":"Escalon","year":"2005","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib7","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.3324\/haematol.2009.011759","article-title":"Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group","volume":"95","author":"Gressin","year":"2010","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib8","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1023\/A:1008392528248","article-title":"CHOP versus MACOP-B in aggressive lymphoma\u2014a Nordic Lymphoma Group randomised trial","volume":"10","author":"Jerkeman","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib9","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group","volume":"116","author":"Schmitz","year":"2010","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib10","doi-asserted-by":"crossref","first-page":"4284","DOI":"10.1182\/blood-2003-02-0542","article-title":"Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma","volume":"102","author":"Tilly","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib11","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ctrv.2012.03.011","article-title":"The role of high dose chemotherapy and autologous stem-cell transplantation in peripheral T-cell lymphoma: a review of the literature and new perspectives","volume":"39","author":"Yared","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib12","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1200\/JCO.2002.02.125","article-title":"Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma","volume":"20","author":"Gisselbrecht","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib13","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1200\/JCO.2000.18.16.3025","article-title":"Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol - A Groupe d'Etude des Lymphomes de l'Adulte Study","volume":"18","author":"Haioun","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib14","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1093\/annonc\/mdh471","article-title":"All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA)","volume":"15","author":"Mounier","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib15","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/annonc\/mdl466","article-title":"The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience","volume":"18","author":"Rodriguez","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib16","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1600-0609.2007.00856.x","article-title":"Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group","volume":"79","author":"Rodriguez","year":"2007","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib17","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","article-title":"Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study","volume":"27","author":"Reimer","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib18","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1093\/annonc\/mdn022","article-title":"Intensive chemotherapy (high-dose CHOP\/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma","volume":"19","author":"Mercadal","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib19","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","article-title":"Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01","volume":"30","author":"d'Amore","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib20","article-title":"Peripheral T-cell lymphoma: the role of hematopoietic stem cell transplantation","author":"Gkotzamanidou","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib21","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3389\/fonc.2013.00138","article-title":"Peripheral T-cell lymphomas: a review of current approaches and hopes for the future","volume":"3","author":"Skarbnik","year":"2013","journal-title":"Front Oncol"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib22","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/ajh.23536","article-title":"The aggressive peripheral T-cell lymphomas: 2013","volume":"88","author":"Armitage","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib23","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1016\/j.bbmt.2013.07.003","article-title":"Allogeneic stem cell transplantation with BEAM and alemtuzumab conditioning immediately after remission induction has curative potential in advanced T-cell non-Hodgkin's lymphoma","volume":"19","author":"Czajczynska","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib24","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.bbmt.2013.01.006","article-title":"Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma","volume":"19","author":"Kanakry","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib25","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.bbmt.2011.11.026","article-title":"Alternate donor hematopoietic cell transplantation (HCT) in non-Hodgkin lymphoma using lower intensity conditioning: a report from the CIBMTR","volume":"18","author":"Hale","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib26","doi-asserted-by":"crossref","first-page":"320624","DOI":"10.1155\/2010\/320624","article-title":"Impact of autologous and allogeneic stem cell transplantation in peripheral T-cell lymphomas","volume":"2010","author":"Reimer","year":"2010","journal-title":"Adv Hematol"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib27","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2141.2011.08651.x","article-title":"Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma)","volume":"153","author":"Dearden","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib28","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.1182\/blood-2008-01-134270","article-title":"ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project","volume":"111","author":"Savage","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib29","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S1470-2045(13)70095-0","article-title":"Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study","volume":"14","author":"Mosse","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib30","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/hon.847","article-title":"Extranodal NK\/T-cell lymphoma: diagnosis and treatment cues","volume":"26","author":"Suzuki","year":"2008","journal-title":"Hematol Oncol"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib31","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1007\/s12185-012-1189-4","article-title":"Current and future management of NK\/T-cell lymphoma based on clinical trials","volume":"96","author":"Yamaguchi","year":"2012","journal-title":"Int J Hematol"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib32","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1200\/JCO.2005.03.2573","article-title":"Radiotherapy as primary treatment for stage IE and IIE nasal natural killer\/T-cell lymphoma","volume":"24","author":"Li","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib33","doi-asserted-by":"crossref","first-page":"4044","DOI":"10.1200\/JCO.2012.45.6541","article-title":"Concurrent chemoradiotherapy for localized nasal natural killer\/T-cell lymphoma: an updated analysis of the Japan clinical oncology group study JCOG0211","volume":"30","author":"Yamaguchi","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib34","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1080\/10245330701214327","article-title":"CMED in the treatment of nasal natural killer cell lymphoma with distant metastases","volume":"12","author":"Aviles","year":"2007","journal-title":"Hematology"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib35","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/j.1349-7006.2008.00768.x","article-title":"Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)\/T-cell lymphoma and leukemia","volume":"99","author":"Yamaguchi","year":"2008","journal-title":"Cancer Sci"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib36","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1182\/blood-2012-05-431460","article-title":"SMILE for natural killer\/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group","volume":"120","author":"Kwong","year":"2012","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib37","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.1200\/JCO.2011.35.6287","article-title":"Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)\/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study","volume":"29","author":"Yamaguchi","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib38","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2010-09-307454","article-title":"Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK\/T-cell lymphoma, a phase 2 study","volume":"117","author":"Jaccard","year":"2011","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib39","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/hon.765","article-title":"Midline NK\/T-cell lymphoma nasal-type: treatment outcome, the effect of L-asparaginase based regimen, and prognostic factors","volume":"24","author":"Yong","year":"2006","journal-title":"Hematol Oncol"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib40","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.critrevonc.2010.06.006","article-title":"Enteropathy-associated T-cell lymphoma","volume":"79","author":"Ferreri","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib41","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1182\/blood-2011-10-385559","article-title":"How I treat enteropathy-associated T-cell lymphoma","volume":"119","author":"Di Sabatino","year":"2012","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib42","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2009-07-231324","article-title":"Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation","volume":"115","author":"Sieniawski","year":"2010","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib43","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1182\/blood-2006-08-042820","article-title":"Autologous hematopoietic stem cell transplantation in refractory celiac disease with aberrant T cells","volume":"109","author":"Al-toma","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib44","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood-2007-02-074641","article-title":"Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial","volume":"110","author":"Gallamini","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib45","doi-asserted-by":"crossref","unstructured":"Marchi E, O'Connor OA. Safety and efficacy of pralatrexate in the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Ther Adv Hematol;3:227-35.","DOI":"10.1177\/2040620712445330"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib46","unstructured":"Marchi E, Mangone M, Zullo K, O'Connor OA. Pralatrexate pharmacology and clinical development. Clin Cancer Res. In press."},{"key":"10.1053\/j.seminhematol.2013.11.001_bib47","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1080\/1042819031000077124","article-title":"Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression","volume":"44","author":"Wang","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib48","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1158\/1078-0432.CCR-05-0331","article-title":"The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-Hodgkin's lymphoma","volume":"12","author":"Toner","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib49","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1158\/1078-0432.CCR-10-0671","article-title":"Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies","volume":"16","author":"Marchi","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib50","doi-asserted-by":"crossref","first-page":"4357","DOI":"10.1200\/JCO.2008.20.8470","article-title":"Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies","volume":"27","author":"O'Connor","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib51","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"O'Connor","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib52","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1200\/JCO.2012.43.7285","article-title":"Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial","volume":"31","author":"Damaj","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib53","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2217\/epi.13.39","article-title":"Combating the epigenome: epigenetic drugs against non-Hodgkin's lymphoma","volume":"5","author":"Hassler","year":"2013","journal-title":"Epigenomics"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib54","doi-asserted-by":"crossref","first-page":"4636","DOI":"10.1182\/blood-2003-09-3068","article-title":"T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance","volume":"103","author":"Piekarz","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib55","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1182\/blood-2010-10-312603","article-title":"Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma","volume":"117","author":"Piekarz","year":"2011","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib56","first-page":"69","volume":"18","author":"Coiffier","year":"2005","journal-title":"Monoclonal antibodies in the treatment of indolent lymphomas Best Pract Res Clin Haematol"},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2013.11.001_bib57","first-page":"135","article-title":"A phase Ib\/II trial of romidepsin in association with CHOP in patients with peripheral T-cell lymphoma (PTCL): the Ro-CHOP study","volume":"31","author":"Dupuis","year":"2013","journal-title":"Hematol Oncol"},{"issue":"Suppl","key":"10.1053\/j.seminhematol.2013.11.001_bib58","article-title":"Belinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (R\/R PTCL): results from the BELIEF trial","volume":"31","author":"O'Connor","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib59","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.ejca.2012.08.017","article-title":"Panobinostat activity in both bexarotene-exposed and -naive patients with refractory cutaneous T-cell lymphoma: results of a phase II trial","volume":"49","author":"Duvic","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib60","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3324\/haematol.10767","article-title":"Expression of CD52 in peripheral T-cell lymphoma","volume":"92","author":"Piccaluga","year":"2007","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib61","doi-asserted-by":"crossref","first-page":"789","DOI":"10.3109\/10428194.2011.629701","article-title":"Overview of alemtuzumab therapy for the treatment of T-cell lymphomas","volume":"53","author":"Zinzani","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib62","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1182\/blood-2003-10-3389","article-title":"A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas","volume":"103","author":"Enblad","year":"2004","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib63","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00280-007-0469-9","article-title":"Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study","volume":"60","author":"Kim","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib64","doi-asserted-by":"crossref","first-page":"397","DOI":"10.18632\/oncotarget.924","article-title":"Linked-in: design and efficacy of antibody drug conjugates in oncology","volume":"4","author":"Feld","year":"2013","journal-title":"Oncotarget"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib65","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/nbt832","article-title":"Development of potent monoclonal antibody auristatin conjugates for cancer therapy","volume":"21","author":"Doronina","year":"2003","journal-title":"Nat Biotechnol"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib66","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","article-title":"Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas","volume":"363","author":"Younes","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib67","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib68","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.2165\/11631090-000000000-00000","article-title":"Mogamulizumab: first global approval","volume":"72","author":"Subramaniam","year":"2012","journal-title":"Drugs"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib69","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1200\/JCO.2009.25.3575","article-title":"Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma","volume":"28","author":"Yamamoto","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib70","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","article-title":"Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study","volume":"30","author":"Ishida","year":"2012","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2013.11.001_bib71","first-page":"109","article-title":"The efficacy and safety of mogamulizumab (KW-0761) in multicentre phase II study for patients with relapsed peripheral or cutaneous T-cell lymphoma","volume":"31","author":"Ueda","year":"2013","journal-title":"Hematol Oncol"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib72","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/cas.12116","article-title":"Stevens-Johnson syndrome associated with mogamulizumab treatment of adult T-cell leukemia\/lymphoma","volume":"104","author":"Ishida","year":"2013","journal-title":"Cancer Sci"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib73","first-page":"717","article-title":"Denileukin diftitox for the treatment of cutaneous T-cell lymphoma","volume":"2","author":"Kaminetzky","year":"2008","journal-title":"Biologics"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib74","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1365-2141.2006.06457.x","article-title":"Phase II trial of denileukin diftitox for relapsed\/refractory T-cell non-Hodgkin lymphoma","volume":"136","author":"Dang","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib75","first-page":"28","article-title":"Phase II study of denileukin diftitox with CHOP chemotherapy in newly-diagnosed PTCL: CONCEPT trial","volume":"Suppl:15s","author":"Foss","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib76","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1002\/cncr.25377","article-title":"Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma","volume":"116","author":"Dueck","year":"2010","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib77","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1016\/j.ejca.2013.04.029","article-title":"A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial","volume":"49","author":"Morschhauser","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib78","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1200\/JCO.2012.46.8793","article-title":"Phase II study of alisertib, a selective aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas","volume":"32","author":"Friedberg","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib79","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1200\/JCO.2011.37.3647","article-title":"Clinicopathologic characteristics of angioimmunoblastic T-cell lymphoma: analysis of the International Peripheral T-Cell Lymphoma Project","volume":"31","author":"Federico","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2013.11.001_bib80","unstructured":"Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumors of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008."}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196313001510?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196313001510?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:22:43Z","timestamp":1758522163000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196313001510"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":80,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S0037196313001510"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2013.11.001","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Changing Landscape of Peripheral T-Cell Lymphoma in the Era of Novel Therapies","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2013.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}